OncoVista Innovative Therapies, Inc.
OncoVista Innovative Therapies, Inc. (OVIT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ovit · pe ratio · data through Dec 31, 2014
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for OncoVista Innovative Therapies, Inc. (OVIT) measures how much investors pay for each dollar of the company's trailing earnings. OVIT's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.12.
Source: FMP · /ratios-ttm · /analyst-estimates · 2014-12-31
PE Ratio History
2004 – 2014 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
OncoVista Innovative Therapies, Inc.You OVIT | $0M | N/A | — | -$0.12 |
 Anthera Pharmaceuticals, Inc. ANTH | $0M | N/A | — | -$1.65 |
 Cotinga Pharmaceuticals Inc. COTQF | $0M | N/A | — | -$0.09 |
 ForU Holdings, Inc. FORU | $0M | N/A | — | -$8.27 |
 Longport, Inc. LPTI | $0M | N/A | — | — |
 Greenwind Holdings Inc. NEWG | $0M | N/A | — | -$0.00 |
 Neurobiological Technologies, Inc. NTII | $0M | N/A | — | $0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2014-12-31Latest FY2014 | — | $-0.12 | — | |
2013-12-31 FY2013 | — | $-0.07 | — | |
2012-12-31 FY2012 | — | $-0.08 | — | |
2011-12-31 FY2011 | — | $-0.10 | — | |
2010-12-31 FY2010 | 0.67x | $0.49 | — | |
2009-12-31 FY2009 | — | $-0.26 | — | |
2008-12-31 FY2008 | — | $-0.41 | — | |
2007-12-31 FY2007 | — | $-0.33 | — | |
2006-12-31 FY2006 | — | $-0.51 | — | |
2005-12-31 FY2005 | — | $-0.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for OncoVista Innovative Therapies, Inc. (OVIT) measures how much investors pay for each dollar of the company's trailing earnings. OVIT's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.12.
Frequently asked questions
OVIT pe ratio · 6 questionsOVIT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.12. Data sourced from Financial Modeling Prep via OVIT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · OncoVista Innovative Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09